216 related articles for article (PubMed ID: 20473949)
21. NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1- and Th2-type tumor-reactive CD4+ T cells.
Zarour HM; Maillere B; Brusic V; Coval K; Williams E; Pouvelle-Moratille S; Castelli F; Land S; Bennouna J; Logan T; Kirkwood JM
Cancer Res; 2002 Jan; 62(1):213-8. PubMed ID: 11782380
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of peripheral blood T lymphocyte surface activation markers and transcription factors in patients with early stage non-small cell lung cancer.
Rutkowski J; Cyman M; Ślebioda T; Bemben K; Rutkowska A; Gruchała M; Kmieć Z; Pliszka A; Zaucha R
Cell Immunol; 2017 Dec; 322():26-33. PubMed ID: 28939130
[TBL] [Abstract][Full Text] [Related]
23. Expression of activation-related molecules on regional lymph node lymphocytes in human lung cancer.
Takenoyama M; Yasumoto K; Harada M; Matsuzaki G; Ishida T; Sugimachi K; Nomoto K
Immunobiology; 1996 Jul; 195(2):140-51. PubMed ID: 8877391
[TBL] [Abstract][Full Text] [Related]
24. Functional CD8+ T cells infiltrate into nonsmall cell lung carcinoma.
Verdegaal EM; Hoogstraten C; Sandel MH; Kuppen PJ; Brink AA; Claas FH; Gorsira MC; Graadt van Roggen JF; Osanto S
Cancer Immunol Immunother; 2007 May; 56(5):587-600. PubMed ID: 16924494
[TBL] [Abstract][Full Text] [Related]
25. Human telomerase reverse transcriptase-specific T-helper responses induced by promiscuous major histocompatibility complex class II-restricted epitopes.
Schroers R; Shen L; Rollins L; Rooney CM; Slawin K; Sonderstrup G; Huang XF; Chen SY
Clin Cancer Res; 2003 Oct; 9(13):4743-55. PubMed ID: 14581345
[TBL] [Abstract][Full Text] [Related]
26. Vaccine-induced CD4+ T cell responses to MAGE-3 protein in lung cancer patients.
Atanackovic D; Altorki NK; Stockert E; Williamson B; Jungbluth AA; Ritter E; Santiago D; Ferrara CA; Matsuo M; Selvakumar A; Dupont B; Chen YT; Hoffman EW; Ritter G; Old LJ; Gnjatic S
J Immunol; 2004 Mar; 172(5):3289-96. PubMed ID: 14978137
[TBL] [Abstract][Full Text] [Related]
27. Expression of HLA-DR is reduced in tumor infiltrating immune cells (TIICs) and regional lymph nodes of non-small-cell lung carcinomas. A putative mechanism of tumor-induced immunosuppression?
Foukas PG; Tsilivakos V; Zacharatos P; Mariatos G; Moschos S; Syrianou A; Asimacopoulos PJ; Bramis J; Fotiadis C; Kittas C; Gorgoulis VG
Anticancer Res; 2001; 21(4A):2609-15. PubMed ID: 11724329
[TBL] [Abstract][Full Text] [Related]
28. A MAGE-1 peptide recognized on HLA-DR15 by CD4(+) T cells.
Chaux P; Lethé B; Van Snick J; Corthals J; Schultz ES; Cambiaso CL; Boon T; van der Bruggen P
Eur J Immunol; 2001 Jun; 31(6):1910-6. PubMed ID: 11433388
[TBL] [Abstract][Full Text] [Related]
29. Vaccination with recombinant NY-ESO-1 protein elicits immunodominant HLA-DR52b-restricted CD4+ T cell responses with a conserved T cell receptor repertoire.
Bioley G; Dousset C; Yeh A; Dupont B; Bhardwaj N; Mears G; Old LJ; Ayyoub M; Valmori D
Clin Cancer Res; 2009 Jul; 15(13):4467-74. PubMed ID: 19531622
[TBL] [Abstract][Full Text] [Related]
30. Immune responses to a class II helper peptide epitope in patients with stage III/IV resected melanoma.
Wong R; Lau R; Chang J; Kuus-Reichel T; Brichard V; Bruck C; Weber J
Clin Cancer Res; 2004 Aug; 10(15):5004-13. PubMed ID: 15297401
[TBL] [Abstract][Full Text] [Related]
31. Generation of dendritic cell-based vaccine using high hydrostatic pressure for non-small cell lung cancer immunotherapy.
Hradilova N; Sadilkova L; Palata O; Mysikova D; Mrazkova H; Lischke R; Spisek R; Adkins I
PLoS One; 2017; 12(2):e0171539. PubMed ID: 28187172
[TBL] [Abstract][Full Text] [Related]
32. Comprehensive Analysis of CD4
Hyun YS; Jo HA; Lee YH; Kim SM; Baek IC; Sohn HJ; Cho HI; Kim TG
Front Immunol; 2020; 11():602014. PubMed ID: 33658991
[TBL] [Abstract][Full Text] [Related]
33. One NY-ESO-1-derived epitope that promiscuously binds to multiple HLA-DR and HLA-DP4 molecules and stimulates autologous CD4+ T cells from patients with NY-ESO-1-expressing melanoma.
Mandic M; Castelli F; Janjic B; Almunia C; Andrade P; Gillet D; Brusic V; Kirkwood JM; Maillere B; Zarour HM
J Immunol; 2005 Feb; 174(3):1751-9. PubMed ID: 15661941
[TBL] [Abstract][Full Text] [Related]
34. The wild-type sequence (wt) p53(25-35) peptide induces HLA-DR7 and HLA-DR11-restricted CD4+ Th cells capable of enhancing the ex vivo expansion and function of anti-wt p53(264-272) peptide CD8+ T cells.
Ito D; Albers A; Zhao YX; Visus C; Appella E; Whiteside TL; DeLeo AB
J Immunol; 2006 Nov; 177(10):6795-803. PubMed ID: 17082593
[TBL] [Abstract][Full Text] [Related]
35. Reactivity of autologous CD4+ T lymphocytes against human melanoma. Evidence for a shared melanoma antigen presented by HLA-DR15.
Takahashi T; Chapman PB; Yang SY; Hara I; Vijayasaradhi S; Houghton AN
J Immunol; 1995 Jan; 154(2):772-9. PubMed ID: 7814883
[TBL] [Abstract][Full Text] [Related]
36. Quantitative tissue analysis and role of myeloid cells in non-small cell lung cancer.
Henick BS; Villarroel-Espindola F; Datar I; Sanmamed MF; Yu J; Desai S; Li A; Aguirre-Ducler A; Syrigos K; Rimm DL; Chen L; Herbst RS; Schalper KA
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35793873
[TBL] [Abstract][Full Text] [Related]
37. An
Lin J; Liu J; Hao SG; Lan B; Zheng XB; Xiong JN; Zhang YQ; Gao X; Chen CB; Chen L; Huang YF; Luo H; Yi YT; Yi X; Lu JP; Zheng XW; Chen G; Wang XF; Chen Y
Front Immunol; 2022; 13():1022598. PubMed ID: 36505399
[TBL] [Abstract][Full Text] [Related]
38. A panel of human cell-based artificial APC enables the expansion of long-lived antigen-specific CD4+ T cells restricted by prevalent HLA-DR alleles.
Butler MO; Ansén S; Tanaka M; Imataki O; Berezovskaya A; Mooney MM; Metzler G; Milstein MI; Nadler LM; Hirano N
Int Immunol; 2010 Nov; 22(11):863-73. PubMed ID: 21059769
[TBL] [Abstract][Full Text] [Related]
39. A repetitive sequence of Epstein-Barr virus nuclear antigen 6 comprises overlapping T cell epitopes which induce HLA-DR-restricted CD4(+) T lymphocytes.
Rajnavölgyi E; Nagy N; Thuresson B; Dosztányi Z; Simon A; Simon I; Karr RW; Ernberg I; Klein E; Falk KI
Int Immunol; 2000 Mar; 12(3):281-93. PubMed ID: 10700463
[TBL] [Abstract][Full Text] [Related]
40. Lack of class II transactivator causes severe deficiency of HLA-DR expression in small cell lung cancer.
Yazawa T; Kamma H; Fujiwara M; Matsui M; Horiguchi H; Satoh H; Fujimoto M; Yokoyama K; Ogata T
J Pathol; 1999 Jan; 187(2):191-9. PubMed ID: 10365094
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
